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Abstract 16 
Intestinal fluids contain several constituents with affinity for cyclodextrins and therefore have 17 
the potential of displacing drugs from the cyclodextrin cavity by competition. In this study, the 18 
solubilizing capacity of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for itraconazole was 19 
studied in presence of selected bile salts and phosphatidylcholine. Despite the fact that these 20 
competing agents significantly lowered the solubility of itraconazole in presence of 21 
cyclodextrins, the addition of concentrated solutions of these bile constituents to a solution 22 
containing itraconazole solubilized by HP-β-CD did not result in precipitation, even at bile salt 23 
and phospholipid concentrations where itraconazole precipitation would be anticipated based 24 
on solubility studies. This phenomenon was further investigated in more dynamic conditions 25 
via in vitro transfer studies, mimicking the gastrointestinal transfer of HP-β-CD solutions 26 
saturated with itraconazole. Intestinal supersaturation upon transfer was observed for all 27 
conditions tested and a concentration dependent impact of bile salts and phospholipids on the 28 
precipitation behavior of itraconazole was demonstrated: high concentrations of bile salts and 29 
phospholipids generated the highest degrees of supersaturation shortly after the transfer step 30 
but also resulted in stronger itraconazole precipitation at later time points. These findings 31 
demonstrate the possible impact of the variable intestinal fluid composition on the behavior of 32 
cyclodextrin containing formulations.  33 
 34 
Keywords (6): itraconazole, cyclodextrin, biorelevant media, gastrointestinal transfer, 35 
supersaturation, precipitation  36 
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1 Introduction 37 
Cyclodextrins (CDs) continue to attract a lot of attention from formulation scientists 38 
because of their excellent solubilizing capacity; they have been used in a multitude of marketed 39 
pharmaceutical products including drugs intended for oral, intravenous, intramuscular or 40 
topical administration (Loftsson and Brewster, 2010). The central cavity of these cyclic 41 
oligosaccharides can be considered a hydrophobic pocket, which plays a crucial role in 42 
improving the solubility of lipophilic drugs. Through formation of inclusion complexes with 43 
these lipophilic compounds, CDs may significantly enhance the bioavailability of drugs 44 
exhibiting poor dissolution characteristics or a limited aqueous solubility. Moreover, recent 45 
observations of spontaneous CD self-assembly suggest that these aggregates can take the form 46 
of micelle-like structures contributing to the solubility of guest compounds through non-47 
inclusion complex formation (He et al., 2008; Loftsson et al., 2004; Ryzhakov et al., 2016).  48 
Although several successful CD containing formulations have been marketed for oral 49 
administration, the gastrointestinal behavior of drugs in presence of CDs is complex and 50 
sometimes difficult to predict. Solubilization of poorly soluble drugs does not necessarily 51 
guarantee an improved intestinal absorption as an increase in solubility often goes hand in hand 52 
with a decrease in the free, bioaccessible fraction of the compound (Katneni et al., 2006; Miller 53 
et al., 2011; Yano et al., 2010). Beig et al. demonstrated that this solubility-permeability 54 
interplay is indeed valid for lipophilic compounds in presence of CDs (Beig et al., 2013). Since 55 
the intestinal absorption of CDs (and CD complexes) is very low to non-existent, the drug has 56 
to be released from the hydrophobic cavity to obtain a satisfactory uptake. Therefore, very high 57 
binding constants or supraoptimal CD concentrations may impede intestinal absorption.  58 
Stella et al. described the mechanisms by which drugs can be released from CD 59 
complexes and mentioned dilution and competitive displacement of drugs from the 60 
hydrophobic cavity as the main factors driving dissociation between drug and CD (Stella et al., 61 
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1999). Although not quite as significant as the dilution factor upon intravenous administration, 62 
a formulation may undergo considerable dilution upon oral ingestion. Factors influencing the 63 
extent of dilution of CDs in a formulation include the volume of the residual gastric fluids and 64 
the possible concomitant intake of water with the formulation. Moreover, Hens et al. recently 65 
demonstrated that in fasted state conditions, the dilution factor upon gastrointestinal transfer is 66 
rather limited and lies close to 1:1 (Hens et al., 2014).  67 
Intestinal fluids contain several agents which have the potential of displacing drugs from 68 
the hydrophobic cavity of CDs, such as bile salts and phospholipids. Furune et al. demonstrated 69 
that α-CDs extract phosphatidylcholine from the mixed micelles present in the intraluminal 70 
environment, hereby diminishing the solubilizing capacity of the intestinal fluids (Furune et al., 71 
2014). In addition to phospholipids, bile salts also exhibit affinity towards CDs. A series of 72 
detailed studies describes the interaction between the most prevalent bile salts in humans and 73 
natural or substituted CDs (Holm et al., 2011, 2007; Schönbeck et al., 2010). A recently 74 
performed study by Olesen et al. rightfully underscores the fact that the intraluminal presence 75 
of bile salts in the small intestine affects the concentration of CD that is theoretically required 76 
to solubilize a drug of interest (Olesen et al., 2015). Although this work relies on a number of 77 
mathematical and physical assumptions, it is a useful reminder for formulation scientists to 78 
consider the complexity of the intraluminal environment.  79 
The highly variable nature of the intestinal fluids was further emphasized by Riethorst 80 
et al. who performed an in-depth characterization of duodenal aspirates from twenty healthy 81 
volunteers (Riethorst et al., 2016). The strongly scattered individual concentrations of different 82 
bile salts, cholesterol, phospholipids and lipid degradation products measured in the intestinal 83 
media advocate the implementation of this variability into the experimental design of in vitro 84 
experiments. Despite the fact that these competing agents may severely influence the 85 
thermodynamic solubility of drugs in presence of CDs, drug displacement does not necessarily 86 
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result in immediate or irreversible precipitation of the drug. For example, Miyake et al. 87 
demonstrated superior absorption of cyclosporine A from a cyclodextrin containing formulation 88 
in rats with continuous bile flow as compared to bile duct-cannulated rats (Miyake et al., 1999). 89 
Moreover, the identification of CDs as suitable precipitation inhibitors, renders this hypothesis 90 
of drug supersaturation upon displacement from CDs all the more likely (M. E. Brewster et al., 91 
2008). 92 
The aim of this study was to evaluate the solubilizing capacity of HP-β-CD for 93 
itraconazole in presence of varying biorelevant concentrations of bile salts and phospholipids. 94 
The antifungal agent itraconazole is marketed as a solution containing 40% of HP-β-CD to 95 
solubilize 10 mg/ml of itraconazole. Itraconazole has a very poor aqueous solubility which 96 
increases significantly upon addition of HP-β-CD (Marcus E. Brewster et al., 2008). In this 97 
investigation, the capacity of bile salts and phospholipids to displace itraconazole from the 98 
hydrophobic cavity of the CDs was assessed. In addition, the effect of displacement by 99 
competing agents on itraconazole supersaturation/precipitation behavior was investigated in 100 
vitro. 101 
  102 
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2 Materials and methods 103 
2.1 Chemicals 104 
Itraconazole and 2-hydroxypropyl-β-CD (HP-β-CD) were kindly provided by Johnson 105 
& Johnson (Beerse, Belgium). The degree of substitution of HP-β-CD was 0.63. Sigma Aldrich 106 
(St. Louis, MO) supplied sodium taurocholate (TC), sodium glycocholate (GC), sodium 107 
glycodeoxycholate (GDC) and sodium glycochenodeoxycholate (GCDC). Sodium acetate 108 
trihydrate and methanol were purchased from VWR International (Leuven, Belgium). 109 
Simulated intestinal fluids (SIF) powder was obtained from Biorelevant (Croydon, UK). Water 110 
was purified using a Maxima system (Elga Ltd., High Wycombe Bucks, UK).  111 
 112 
2.2 Media 113 
Fasted (FaSSIF) and fed (FeSSIF) state simulated intestinal fluids and fasted state 114 
simulated gastric fluids (SGF) were made according to the manufacturer’s preparation protocol 115 
(Biorelevant®, Croydon, UK). FaSSIF was prepared by dissolving SIF powder (2.24 mg/mL) 116 
in a phosphate buffer (28.4 mM, pH 6.5) and a pH modified version of FeSSIF was prepared 117 
by dissolving SIF powder (11.2 mg/mL) in the same phosphate buffer (pH 6.5) instead of the 118 
commonly used acetate buffer (pH 5). This was done to exclude the pH as a possible 119 
confounding factor. SGF was made by dissolving SIF powder (0.06 mg/mL) in an HCl/NaCl 120 
solution (pH 1.6). SIF powder contains the bile salt taurocholate and the phospholipid 121 
phosphatidylcholine at a ratio of 4:1. A concentration of 1 mg SIF powder per ml of medium is 122 
equivalent with 1.34 mM taurocholate and 0.33 mM phosphatidylcholine. Consequently, 123 
FaSSIF contains 3 mM of taurocholate and 0.75 mM of phosphatidylcholine and FeSSIF 124 
contains 15 mM of taurocholate and 3.75 mM of phosphatidylcholine. 125 
To correct for the 1:1 dilution effect during the gastrointestinal transfer studies, a series 126 
of double concentrated intestinal media were prepared by dissolving 5, 15 and 20 mg of SIF 127 
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powder per ml of a double concentrated phosphate buffer (56.8 mM, pH 7.5). A control 128 
condition without SIF powder was also included. The pH was set at 7.5 to end up with media 129 
at a pH of 6.5 containing 0, 2.5, 7.5 and 10 mg of SIF powder per ml after addition of equal 130 
volumes of SGF.  131 
 132 
2.3 Solubility measurements 133 
The apparent solubility of itraconazole was determined in several biorelevant media, 134 
including simulated gastric and intestinal fluids in presence or absence of varying 135 
concentrations of HP-β-CD, bile salts and phospholipids as well as in blank transfer media. The 136 
latter are the media resulting from the 1:1 dilution of SGF containing varying concentrations of 137 
HP-β-CD in the double concentrated phosphate buffer (pH 7.5) containing varying 138 
concentrations of bile salts and phosphatidylcholine.  139 
All solubility experiments were performed in triplicate. Approximately 3 mg of 140 
itraconazole was added to microcentrifuge tubes containing 0.5 ml of medium and placed in a 141 
prewarmed shaking incubator [37°C at 175 rpm (KS 4000 i control incubator from Ika (Staufen, 142 
Germany))] for 24 h. The solid phase was separated from the dissolved part using centrifugation 143 
(15 min, 20.817 g at 37°C). The top layer was carefully removed by aspiration. The supernatant 144 
was diluted 1/10 or 1/100 in methanol:water (50:50 v/v) and itraconazole was quantified using 145 
an HPLC system with UV detection. 146 
 147 
2.4 Displacement studies 148 
The displacement of itraconazole from the CD cavity of HP-β-CD was evaluated by 149 
adding concentrated solutions of competing agents to a predefined itraconazole concentration 150 
solubilized by a predefined concentration of HP-β-CD. More specifically, a concentrated 151 
solution of SIF powder or selected bile salts in phosphate buffer was titrated into a solution of 152 
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20 µM or 40 µM, respectively, of itraconazole in 4% HP-β-CD. The concentrated solutions 153 
were prepared in such a way that the final concentrations of the media upon titration amounted 154 
to 4.1, 5.9, 7.7, 9.5 or 11.2 mg of SIF per ml of buffer or 10 mM of TC, GC, GDC or GCDC 155 
per ml of buffer. Experiments were performed in test tubes placed in a water bath maintained 156 
at 37°C. Media were stirred using magnetic stirring bars rotating at 400 rpm. Samples (50 µl) 157 
were taken from the media at predetermined time points and were centrifuged immediately (10 158 
min, 20.817 g at 37°C). The supernatant was diluted 1/100 in methanol:water (50:50 v/v) and 159 
quantified using an HPLC system with UV detection. 160 
 161 
2.5 In vitro transfer studies 162 
In vitro transfer studies to mimic the gastrointestinal transfer were performed under 163 
various conditions. These experiments are referred to as ‘gastrointestinal transfer studies’ 164 
throughout the manuscript. The gastric compartment consisted out of SGF in absence of CDs 165 
or in presence of 2%, 4%, 8% or 12% HP-β-CD saturated up to 75-80% with itraconazole. 166 
Incomplete saturation was selected as this significantly decreased the preparation time of the 167 
media used in the gastric compartment. The intestinal compartment contained double 168 
concentrated phosphate buffer (pH 7.5) in absence or in presence of 5mg or 20 mg SIF powder 169 
per ml of phosphate buffer. Both gastric and intestinal fluids were prewarmed in test tubes in a 170 
water bath maintained at 37°C. The transfer experiment was initiated by adding 1 ml of the 171 
gastric compartment to 1 ml of the intestinal compartment. Upon dilution, the pH of the 172 
simulated intestinal fluids dropped from 7.5 to 6.5. The intestinal compartment was stirred using 173 
magnetic stirring bars rotating at 400 rpm. Samples (50 µl) were taken from the medium at 174 
predetermined time points and immediately centrifuged (10 min, 20.817g at 37°C). The 175 
supernatant was diluted 1/100 in methanol:water (50:50 v/v) and quantified using an HPLC 176 
system with UV detection. 177 
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For the concentrations measured in the intestinal compartment during the transfer 178 
studies, degrees of supersaturation (DS) were also calculated. The DS was calculated by 179 
dividing the concentration measured at a particular time point, by the equilibrium solubility of 180 
the corresponding drug in exactly the same medium. 181 
 182 
2.6 Analysis 183 
Itraconazole concentrations were determined by reversed phase HPLC with UV 184 
detection. A Hitachi LaChrom Elite HPLC system was used consisting of an L-2130 pump, an 185 
L-2200 autosampler and an L-2400 UV detector and EZChrom Elite was used as the software 186 
program to integrate the itraconazole peaks (VWR, Leuven, Belgium). The used column was a 187 
Waters Nova-Pak® RP-18 (100 x 8 mm, 4 µm) inserted into a radial compression module 188 
(Waters, Milford, MA, USA). For all samples, an injection volume of 95 µl was used. The flow 189 
rate was set at 1.4 ml/min. The mobile phase consisted of a 25 mM acetate buffer (pH 3.5) and 190 
methanol used at a ratio of 82:18. Itraconazole concentrations were monitored by UV 191 
absorbance measurement at a wavelength of 265 nm and the retention time was 6.5 min. 192 
Calibration curves were linear over the range of 5 µM to 40 nM. The assessment of intraday 193 
repeatability, determined at 0.1 and 1 µM resulted in a relative standard deviation (n=5) of 8.3 194 
and 1.1%, respectively; the deviation from the theoretical concentration amounted to 6.7 and 195 
1.8%, respectively.  196 
  197 
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3 Results and discussion 198 
The capacity of HP-β-CD to solubilize itraconazole in a biorelevant environment was 199 
evaluated by performing solubility, displacement and gastrointestinal transfer studies using 200 
simulated media reflecting the composition of human gastric and intestinal fluids. While 201 
solubility studies are indicative for the concentrations that can be reached in a saturated system 202 
in equilibrium, displacement and gastrointestinal transfer studies reflect the dynamic nature of 203 
the gastrointestinal tract and concentrations measured in these experiments may deviate 204 
significantly from the apparent solubility. Moreover, in the solubility determinations, the 205 
experiments are initiated by the addition of itraconazole powder to a solution of CDs and/or 206 
bile constituents whereas in the displacement and transfer experiments, the solutions initially 207 
contain CDs and itraconazole after which they are brought into contact with bile salts and/or 208 
phospholipids by titration (displacement studies) or through a transfer step from the stomach 209 
compartment to the intestinal compartment (transfer studies).  210 
 211 
3.1 Solubility of itraconazole in complex CD containing biorelevant media 212 
In a first approach to evaluate the impact of phospholipids and bile salts on the 213 
solubilizing capacity of HP-β-CD for itraconazole, solubility measurements were performed in 214 
FaSSIF and FeSSIF in presence of increasing concentrations of HP-β-CD. FaSSIF and FeSSIF 215 
are well characterized simulated intestinal fluids representing the fasted and fed state, 216 
respectively, and they are widely used for dissolution and solubility testing.  217 
Both in FaSSIF and FeSSIF, itraconazole concentrations increased with increasing CD 218 
concentrations, indicating that the solubility of itraconazole significantly benefits from 219 
inclusion of the compound in the CD cavity (Figure 1). Brewster et al. already reported a 220 
positive effect of HP-β-CD on the solubility of itraconazole in several aqueous buffer systems 221 
(Marcus E. Brewster et al., 2008). An important observation is that the itraconazole solubility 222 
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in FeSSIF was consistently lower than the solubility in FaSSIF, except for the condition where 223 
no CD was present. In the latter case, the higher abundance of mixed micelles in FeSSIF results 224 
in a superior solubility of itraconazole as compared to the simulated fluids of the fasted state. 225 
On the other hand, in presence of CDs, the relatively high concentrations of bile salts and 226 
phospholipids appeared to exclude a proportion of the itraconazole from the CD cavity, 227 
resulting in a lower itraconazole solubility. Furthermore, the ratio of the concentration measured 228 
in FeSSIF and in FaSSIF, depicted in Figure 1 demonstrates that the relative importance of this 229 
itraconazole exclusion phenomenon decreased with increasing CD concentration. At a 230 
concentration of 2% HP-β-CD, the itraconazole solubility in FeSSIF is only 27% of the 231 
solubility in FaSSIF, whereas at a CD concentration of 16% this ratio is 88%.  232 
The simulated intestinal fluids used in this first solubility study contain sodium 233 
taurocholate as the sole type of bile salt. Recently, Riethorst et al. published a detailed 234 
characterization of human intestinal fluids in the fasted and fed state and confirmed that in 235 
addition to the taurine conjugates, the glycine conjugates are well represented bile salts in these 236 
media (Riethorst et al., 2016).  237 
To compare the ability of the different bile salts to expel itraconazole from the CD 238 
cavity, the solubility of itraconazole in 4% HP-β-CD was evaluated in presence or absence of 239 
four of the most prominent bile salts present in human intestinal fluids (Figure 2). A lower 240 
solubility of itraconazole was measured in presence of all bile salts tested, indicating that both 241 
taurine and glycine conjugates have the potential to exclude itraconazole from the CD cavity. 242 
Sodium taurocholate (TC), the bile salt that is most commonly used in simulated intestinal 243 
fluids, appeared to cause the strongest drop in the solubilizing capacity of HP-β-CD. This is 244 
remarkable as the stability constants of the taurocholate - HP-β-CD complex reported by 245 
Schönbeck et al. were lower than the stability constants measured for glycodeoxycholate (GDC) 246 
and glycochenodeoxycholate (GCDC) (Schönbeck et al., 2010). Apparently, these higher 247 
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stability constants for some of the glycine conjugates, do not result in a stronger impact on the 248 
solubilizing capacity of HP-β-CD for itraconazole.  249 
Although it can be useful to consider the impact of isolated intraluminal substances such 250 
as bile salts and phospholipids on the solubilizing capacity of a CD containing formulation, it 251 
is important to acknowledge the fact that mutual interactions between these substances may 252 
severely affect the outcome of the experiment. Indeed, aqueous media containing both bile salts 253 
and phospholipids are known to be highly different from simple bile salt solutions. Both size 254 
and solubilization capacity of bile salt micelles tend to increase significantly when 255 
phospholipids are added to the solvent system, generating mixed micellar media (Hörter and 256 
Dressman, 2001). To evaluate the effect of the presence of phosphatidylcholine on the 257 
solubilizing capacity of the CD containing biorelevant media, the solubility of itraconazole in 258 
aqueous buffers containing increasing concentrations of HP-β-CD was compared with its 259 
solubility under experimental conditions in which only taurocholate or both taurocholate and 260 
phosphatidylcholine were added to the CD containing medium (Figure 3). Interestingly, while 261 
the solubility of itraconazole in presence of both taurocholate and phosphatidylcholine was 262 
consistently lower than in the control situation (phosphate buffer, pH 6.5), this was not the case 263 
when only taurocholate was added to the buffer. Despite the fact that equal concentrations of 264 
taurocholate (10 mM) were present in the two micellar media, the addition of 265 
phosphatidylcholine clearly induced a shift in the equilibrium interplay between itraconazole, 266 
HP-β-CD and the micellar fraction in the solvent system: at the lower CD concentrations of 1 267 
and 2%, itraconazole solubility in presence of both taurocholate and phosphatidylcholine is 268 
significantly lower than in presence of only taurocholate. This empirically observed divergence 269 
between mixed micellar media and media containing only bile salt micelles, advocates a 270 
cautious interpretation of in vitro or mathematical models that do not fully appreciate the 271 
complex nature of biorelevant media.  272 
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When the CD concentration increases further up to 4%, the impact of the additional 273 
presence of phosphatidylcholine appears to abate. This is in accordance with the findings 274 
presented in Figure 1, where the impact of the concentration of biorelevant components 275 
decreased with increasing CD concentrations. 276 
 277 
3.2 Displacement of itraconazole from HP-β-CD: supersaturation/precipitation behavior 278 
Solubility studies are useful as they offer valuable information about the itraconazole 279 
concentrations that can be expected when the system is in equilibrium. In the dynamic 280 
environment of the gastrointestinal tract, however, a formulation is subjected to multiple 281 
processes and drugs are often in a thermodynamically unstable state. Supersaturation in human 282 
intestinal fluids has been described for several compounds, both in vivo and in vitro (Bevernage 283 
et al., 2013; Psachoulias et al., 2011; Stappaerts et al., 2015). 284 
In an effort to evaluate the immediate effects of bile secretion on the intestinal behavior 285 
of itraconazole in presence of HP-β-CD, a displacement study was performed in which a 286 
concentrated solution of taurocholate and phosphatidylcholine was titrated into a solution 287 
containing 20 µM of itraconazole in 4% HP-β-CD. Figure 4 depicts the concentrations that 288 
were measured upon adding increasing amounts of taurocholate and phosphatidylcholine. 289 
Notwithstanding the fact that with increasing concentrations of bile salts and phospholipids the 290 
solubilizing capacity of the medium, determined by solubility studies as described in the 291 
previous section, dropped significantly (triangles in Figure 4), itraconazole remained in solution 292 
(squares in Figure 4). Even 100 min after the addition of the highest amount of taurocholate 293 
and phosphatidylcholine tested, no precipitation of itraconazole could be demonstrated. This is 294 
interesting, as these findings support the mechanism of itraconazole supersaturation induction 295 
through secretion of bile and subsequent competition between itraconazole and bile constituents 296 
for the CD cavity.  297 
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 A similar displacement study was performed to evaluate the short term effects of the 298 
presence of different bile salts on the behavior of itraconazole. Analogously to the concentrated 299 
simulated intestinal fluid solution used in the previous experiment, a concentrated bile salt 300 
solution was titrated into a 4% HP-β-CD solution containing 40 µM of itraconazole. The 301 
targeted bile salt concentration upon addition of the concentrated solution was 10 mM, which 302 
is situated between the bile salt concentrations used in FaSSIF and FeSSIF and is well within 303 
ranges reported in man (Riethorst et al., 2016).  304 
 Figure 5 displays the itraconazole concentrations measured in the CD containing media 305 
after addition of the different bile salts. Based on the solubility of itraconazole in these media, 306 
precipitation of itraconazole would be expected (Figure 2). For three of the four bile salts tested 307 
(the glycine conjugates), no precipitation was observed over a period of 120 min. Only for 308 
taurocholate, minor precipitation was observed, clearly indicating that competition between 309 
itraconazole and the bile salts is genuinely taking place in the medium causing itraconazole to 310 
be partially displaced from the CD cavity. A comparison with the solubility experiment 311 
illustrated in Figure 2 shows that in presence of bile salts, concentrations of itraconazole in the 312 
displacement study consistently exceed the apparent solubility values measured after 24 h, 313 
again confirming generation of itraconazole supersaturation upon displacement from the CD 314 
cavity. 315 
 A supersaturated solution is metastable and under the experimental conditions described 316 
here, itraconazole will eventually precipitate. In vivo, however, the supersaturated fraction of 317 
itraconazole, being excluded from the CD cavity, is freely bioaccessible and may be 318 
immediately absorbed by the enormous surface area of the small intestine. Therefore, the 319 
combination of solubility and displacement studies is a useful approach to predict the 320 
performance of CD containing formulations in a biorelevant context.  321 
 322 
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3.3 Gastrointestinal transfer studies 323 
The impact of the stomach on the intestinal absorption of both basic and acidic compounds has 324 
been abundantly described (Brouwers et al., 2007; Van Den Abeele et al., 2016; Walravens et 325 
al., 2011). As compared to their solubility in intestinal fluids, basic compounds generally 326 
exhibit a superior solubility in the low pH ranges of the gastric fluids. Recent clinical findings 327 
from our research group clearly demonstrate gastrointestinal transfer to result in itraconazole 328 
supersaturation in the small intestine (manuscript in preparation). To include this dynamic 329 
process in our mechanistic study, the behavior of itraconazole following gastrointestinal 330 
transfer was studied by performing in vitro transfer experiments in presence of relevant 331 
concentrations of HP-β-CD and varying concentrations of bile salts and phospholipids. The 332 
gastric compartment contained increasing concentrations of HP-β-CD saturated with 333 
itraconazole, the highest of which amounted to 12%. This percentage was calculated based on 334 
the intake of 20 ml of a 40% HP-β-CD containing itraconazole solution (cfr. Sporanox®) and a 335 
residual gastric volume of 50 ml. The in vivo transfer from the stomach to the small intestine 336 
was simulated by a 1:1 dilution from the compartment containing the simulated gastric fluids 337 
into the intestinal compartment containing a double concentrated phosphate buffer in presence 338 
or absence of varying concentrations of taurocholate and phosphatidylcholine. The dilution 339 
factor of 1:1 was selected in accordance with a study reported by Hens et al. describing the 340 
gastrointestinal transfer of a solution containing the non-absorbable marker paromomycin 341 
(Hens et al., 2014). In the intestinal compartment, different concentrations of taurocholate and 342 
phosphatidylcholine were used. The selection of taurocholate and phosphatidylcholine seemed 343 
reasonable based on the observed discrepancy in solubilizing capacity of HP-β-CD in presence 344 
of bile salts alone or in media containing both taurocholate and phosphatidylcholine (Figure 3), 345 
combined with the observation that taurocholate displayed the strongest impact on itraconazole 346 
displacement (Figure 2 and Figure 5).  347 
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In a first step, the solubility of itraconazole was determined in simulated gastric fluids 348 
and in the blank transfer media. These are the media resulting from the 1:1 dilution of SGF 349 
containing the selected concentrations of HP-β-CD in double concentrated phosphate buffer 350 
(pH 7.5) supplemented with the selected concentrations of bile salts and phosphatidylcholine 351 
(Table 1). Solubility values in presence of equal CD concentrations were significantly higher 352 
in the simulated gastric fluids than in the simulated intestinal fluids. Brewster et al. suggested 353 
that at low pH values, both drug protonation and changes in the interaction between itraconazole 354 
and HP-β-CD are responsible for the high solubility of itraconazole in gastric media containing 355 
HP-β-CD (Marcus E. Brewster et al., 2008). In all CD containing intestinal media tested, 356 
itraconazole solubility decreased with increasing concentrations of bile salts and phospholipids, 357 
again confirming the exclusion of itraconazole from the CD cavity by the constituents of the 358 
biorelevant fluids. Evidently, in intestinal media containing equal amounts of phospholipids 359 
and bile salts, solubility increased with increasing CD concentration.  360 
Table 1: Apparent solubility of itraconazole in simulated gastric fluids and simulated intestinal fluids (blank 361 
transfer medium) in presence of increasing concentrations of HP-β-CD. Simulated intestinal fluids with 362 
various concentrations of taurocholate and phosphatidylcholine were tested. Solubility values are presented 363 
in µM and represent mean ± SD (n=3). 364 
 365 
  366 
 Figure 6 presents an overview of the transfer experiments that were conducted: 367 
solubility values in the transfer medium are depicted as well as the concentrations that were 368 
measured in the intestinal compartment in function of time. For all conditions, a similar pattern 369 
could be observed in the concentration-time profiles: a peak concentration was measured in the 370 
earliest time point after which the itraconazole concentrations dropped steadily, pursuing the 371 
apparent solubility. Regardless of the concentrations of HP-β-CD, taurocholate and 372 
SGF SIF 0 mg/ml 2.5 mg/ml 7.5 mg/ml 10 mg/ml 
0% HP-β-CD 7.4±1.3 0% HP-β-CD 4.5±2.5 1.3±0.2 1.0±0.1 1.2±0.1 
2% HP-β-CD 84.2±5.2 1% HP-β-CD 4.2±1.0 2.3±0.3 1.8±0.2 1.6±0.3 
4% HP-β-CD 233.1±18.5 2% HP-β-CD 10.4±0.3 5.2±0.3 2.9±0.2 2.7±0.1 
8% HP-β-CD 627.7±21.8 4% HP-β-CD 28.6±5 16.4±0.4 9.6±0.5 8.0±0.6 
12% HP-β-CD 1051.5±68.9 6% HP-β-CD 47.3±5.3 32.4±0.6 21.9±0.8 19.3±0.4 
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phosphatidylcholine present in the intestinal compartment, a period of itraconazole 373 
supersaturation could be demonstrated. The duration of this period as well as the extent of 374 
supersaturation increased strongly with increasing concentration of HP-β-CD. This observation 375 
can be explained by the ability of hydrophilic CDs to function as a precipitation inhibitor 376 
maintaining supersaturation (M. E. Brewster et al., 2008).  377 
 Interestingly, a concentration dependent impact of bile salts and phospholipids on the 378 
itraconazole concentration-time profiles was demonstrated (grey versus black bars in Figure 6). 379 
While itraconazole concentrations in presence of taurocholate and phosphatidylcholine at the 380 
earliest time point were at least equally high as the concentrations in absence of these bile 381 
constituents, solubilized concentrations of itraconazole decreased at a higher rate in the 382 
condition with the highest concentrations of bile salts and phospholipids tested (10 mg SIF/ml) 383 
than in the control condition (0 mg SIF/ml). At moderate concentrations (2.5 mg SIF/ml), the 384 
concentration of itraconazole was consistently similar to the control condition. These findings 385 
indicate that high concentrations of bile salts and phospholipids may drive itraconazole 386 
precipitation as they are able to expel itraconazole from the CD cavity. 387 
 In addition to the absolute concentrations of itraconazole, Figure 6 depicts the degrees 388 
of supersaturation (i.e. the itraconazole concentrations measured after the transfer step divided 389 
by their apparent solubility) that are reached in the intestinal media. Especially at the early time 390 
points and for the highest concentrations of bile constituents, high degrees of supersaturation 391 
are reached. The lower apparent solubility as compared to the control condition combined with 392 
the similar concentrations measured at the earliest time points, results in degrees of 393 
supersaturation as high as 12, 14 and 12 for the condition with the highest taurocholate and 394 
phospholipid concentration in presence of 2, 4 and 6% of HP-β-CD, respectively. These degrees 395 
of supersaturation are much higher than in absence of bile constituents. Moreover, the extent of 396 
supersaturation (i.e. the AUC of the concentrations measured over the period of 100 min minus 397 
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the AUC of the apparent solubility maintained over 100 min) in presence of bile constituents 398 
also supersedes the extent of supersaturation in absence of bile salts and phospholipids. As the 399 
supersaturated fraction of itraconazole is readily bioaccessible and escapes the solubility-400 
permeability trade-off, the effect of endogenous compounds on supersaturation/precipitation 401 
behavior of a drug in presence of CDs is very likely to affect the absorption rate and the extent 402 
of absorption of drugs.  403 
 404 
4 Conclusion 405 
The results of this study demonstrate the importance of evaluating formulation 406 
performance in media that reflect an environment that is relevant for the site where the 407 
formulation has its impact on bioavailability. Data clearly indicate that competing agents 408 
present in the small intestine may diminish the solubilizing capacity of CDs. Bile salts and 409 
phospholipids were shown to exclude itraconazole from the CD cavity of HP-β-CD in solubility 410 
studies. Moreover, displacement studies and gastrointestinal transfer studies, designed to reflect 411 
the dynamic nature of the gastrointestinal environment, revealed the ability of these competing 412 
agents to displace solubilized itraconazole from the CD cavity. Comparison with solubility data 413 
learned that this displacement can trigger supersaturation possibly leading to improved 414 
intestinal absorption.  415 
 416 
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Legend for figures 510 
 511 
Figure 1: Apparent solubility of itraconazole in FaSSIF (white bars) and FeSSIF (black bars). 512 
Open diamonds represent the ratio of the solubility of itraconazole in FaSSIF and in FeSSIF. 513 
Bars represent the mean + SD (n=3) 514 
 515 
Figure 2: Apparent solubility of itraconazole in 4% of HP-β-CD in presence or absence of 10 516 
mM of TC, GC, GDC or GCDC. Bars represent mean + SD (n=3). 517 
 518 
Figure 3: Apparent solubility of itraconazole in phosphate buffer (white bars), phosphate buffer 519 
+ 10 mM taurocholate (grey bars) or phosphate buffer + 10mM taurocholate and 2.5 mM 520 
phosphatidylcholine in presence of increasing concentrations of HP-β-CD. Bars represent mean 521 
+ SD. 522 
 523 
Figure 4: Triangles represent the apparent solubility of itraconazole in 4% of HP-β-CD in a 524 
phosphate buffer in presence of increasing concentrations of taurocholate and 525 
phosphatidylcholine. Squares represent the concentrations measured in the displacement study, 526 
100 min after the addition of concentrated solutions of SIF powder to a phosphate buffer 527 
containing 20 µM of itraconazole in a 4% HP-β-CD solution in a phosphate buffer. Symbols 528 
represent mean ± SD (n=3). 529 
 530 
Figure 5: Concentrations measured during the displacement study in function of time upon the 531 
addition of concentrated bile salt solutions to a phosphate buffer containing 40 µM of 532 
itraconazole in a 4% HP-β-CD solution in a phosphate buffer. Bars represent mean ± SD (n=3). 533 
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Figure 6: Apparent solubility measured in blank transfer medium and time dependent 534 
concentrations measured in the intestinal compartment during the gastrointestinal transfer 535 
studies in absence of SIF powder (white bars), in presence of 2.5 mg SIF powder per ml of 536 
medium (grey bars) and in presence of 10 mg SIF powder per ml of medium (black bars). The 537 
degrees of supersaturation (DS) for itraconazole in absence (squares) and in presence of 2.5 538 
(crosses) and 10 (circles) mg SIF powder per ml of medium are depicted as well. Bars represent 539 
mean + SD (n=3). 540 
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